Pathfinder Cell Therapy (Pathfinder Cell Therapy) Momentum Rank : 0 (As of Jun. 07, 2024)

View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Momentum Rank?

Pathfinder Cell Therapy has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Pathfinder Cell Therapy Momentum Rank Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Bow Street, Cambridge, MA, USA, 02138

Website

http://www.pathfindercelltherapy.com

Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.

Executives

John J Alam	director	130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines